(Q53061383)
Statements
The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy. (English)
S Lichtiger
D G Binion
D C Wolf
D H Present
A G Bensimon
E Wu
A P Yu
A T Cardoso
J Chao
P M Mulani
K G Lomax
J D Kent
28 September 2010
32
10
1228-1239